Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57


A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.

Goldstein LJ, Perez RP, Yardley D, Han LK, Reuben JM, Gao H, McCanna S, Butler B, Ruffini PA, Liu Y, Rosato RR, Chang JC.

Breast Cancer Res. 2020 Jan 10;22(1):4. doi: 10.1186/s13058-019-1243-8.


A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).

Patel TA, Ensor JE, Creamer SL, Boone T, Rodriguez AA, Niravath PA, Darcourt JG, Meisel JL, Li X, Zhao J, Kuhn JG, Rosato RR, Qian W, Belcheva A, Schwartz MR, Kaklamani VG, Chang JC.

Breast Cancer Res. 2019 Sep 2;21(1):100. doi: 10.1186/s13058-019-1186-0.


VraSR and Virulence Trait Modulation during Daptomycin Resistance in Methicillin-Resistant Staphylococcus aureus Infection.

Taglialegna A, Varela MC, Rosato RR, Rosato AE.

mSphere. 2019 Feb 13;4(1). pii: e00557-18. doi: 10.1128/mSphere.00557-18.


Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.

Rosato RR, Dávila-González D, Choi DS, Qian W, Chen W, Kozielski AJ, Wong H, Dave B, Chang JC.

Breast Cancer Res. 2018 Sep 5;20(1):108. doi: 10.1186/s13058-018-1037-4.


Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.

González-González A, Muñoz-Muela E, Marchal JA, Cara FE, Molina MP, Cruz-Lozano M, Jiménez G, Verma A, Ramírez A, Qian W, Chen W, Kozielski AJ, Elemento O, Martín-Salvago MD, Luque RJ, Rosa-Garrido C, Landeira D, Quintana-Romero M, Rosato RR, García MA, Ramirez-Tortosa CL, Kim H, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Lorente JA, Sánchez-Rovira P, Chang JC, Granados-Principal S.

Clin Cancer Res. 2018 Nov 15;24(22):5697-5709. doi: 10.1158/1078-0432.CCR-17-3125. Epub 2018 Jul 16.


Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.

Dávila-González D, Choi DS, Rosato RR, Granados-Principal SM, Kuhn JG, Li WF, Qian W, Chen W, Kozielski AJ, Wong H, Dave B, Chang JC.

Clin Cancer Res. 2018 Mar 1;24(5):1152-1162. doi: 10.1158/1078-0432.CCR-17-1437. Epub 2018 Jan 4.


HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway.

Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, Lopez-Berestein G, Landis MD, Rosato RR, Dave B, Wong S, Marchetti D, Sood AK, Chang JC.

Stem Cell Reports. 2018 Jan 9;10(1):212-227. doi: 10.1016/j.stemcr.2017.11.010. Epub 2017 Dec 14.


Molecular Bases Determining Daptomycin Resistance-Mediated Resensitization to β-Lactams (Seesaw Effect) in Methicillin-Resistant Staphylococcus aureus.

Renzoni A, Kelley WL, Rosato RR, Martinez MP, Roch M, Fatouraei M, Haeusser DP, Margolin W, Fenn S, Turner RD, Foster SJ, Rosato AE.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01634-16. doi: 10.1128/AAC.01634-16. Print 2017 Jan.


Histone deacetylase inhibitors activate NF-κB in human leukemia cells through an ATM/NEMO-related pathway.

Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S.

J Biol Chem. 2016 Aug 19;291(34):17535. doi: 10.1074/jbc.A109.095208. No abstract available.


Oligonucleotide aptamers: new tools for targeted cancer therapy.

Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y.

Mol Ther Nucleic Acids. 2014 Aug 5;3:e182. doi: 10.1038/mtna.2014.32.


Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.

Fernandez R, Paz LI, Rosato RR, Rosato AE.

Antimicrob Agents Chemother. 2014 Oct;58(10):5736-46. doi: 10.1128/AAC.03019-14. Epub 2014 Jul 14.


TCA cycle-mediated generation of ROS is a key mediator for HeR-MRSA survival under β-lactam antibiotic exposure.

Rosato RR, Fernandez R, Paz LI, Singh CR, Rosato AE.

PLoS One. 2014 Jun 16;9(6):e99605. doi: 10.1371/journal.pone.0099605. eCollection 2014.


Exposure of clinical MRSA heterogeneous strains to β-lactams redirects metabolism to optimize energy production through the TCA cycle.

Keaton MA, Rosato RR, Plata KB, Singh CR, Rosato AE.

PLoS One. 2013 Aug 5;8(8):e71025. doi: 10.1371/journal.pone.0071025. Print 2013.


Targeting of PBP1 by β-lactams determines recA/SOS response activation in heterogeneous MRSA clinical strains.

Plata KB, Riosa S, Singh CR, Rosato RR, Rosato AE.

PLoS One. 2013 Apr 23;8(4):e61083. doi: 10.1371/journal.pone.0061083. Print 2013.


β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives.

Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, Rosato RR, Rosato AE.

Antimicrob Agents Chemother. 2012 Dec;56(12):6192-200. doi: 10.1128/AAC.01525-12. Epub 2012 Sep 17.


VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus.

Mehta S, Cuirolo AX, Plata KB, Riosa S, Silverman JA, Rubio A, Rosato RR, Rosato AE.

Antimicrob Agents Chemother. 2012 Jan;56(1):92-102. doi: 10.1128/AAC.00432-10. Epub 2011 Oct 10.


Fate of mutation rate depends on agr locus expression during oxacillin-mediated heterogeneous-homogeneous selection in methicillin-resistant Staphylococcus aureus clinical strains.

Plata KB, Rosato RR, Rosato AE.

Antimicrob Agents Chemother. 2011 Jul;55(7):3176-86. doi: 10.1128/AAC.01119-09. Epub 2011 May 2.


Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway.

Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S.

J Biol Chem. 2010 Mar 26;285(13):10064-77. doi: 10.1074/jbc.M109.095208. Epub 2010 Jan 11. Retraction in: J Biol Chem. 2016 Aug 19;291(34):17535.


HDAC Inhibitors--CHI's Third Annual Conference.

Rosato RR.

IDrugs. 2010 Jan;13(1):13-5.


Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Rosato RR, Almenara JA, Maggio SC, Coe S, Atadja P, Dent P, Grant S.

Mol Cancer Ther. 2008 Oct;7(10):3285-97. doi: 10.1158/1535-7163.MCT-08-0385.


RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis.

Colo GP, Rosato RR, Grant S, Costas MA.

FEBS Lett. 2007 Oct 30;581(26):5075-81. Epub 2007 Oct 2.


Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.

Rosato RR, Almenara JA, Kolla SS, Maggio SC, Coe S, Giménez MS, Dent P, Grant S.

Mol Cancer Ther. 2007 Feb;6(2):692-702.


Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.

Rosato RR, Almenara JA, Maggio SC, Atadja P, Craig R, Vrana J, Dent P, Grant S.

Mol Cancer Ther. 2005 Nov;4(11):1772-85.


The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide.

Rosato RR, Maggio SC, Almenara JA, Payne SG, Atadja P, Spiegel S, Dent P, Grant S.

Mol Pharmacol. 2006 Jan;69(1):216-25. Epub 2005 Sep 27. Retraction in: Mol Pharmacol. 2019 Apr;95(4):336.


Histone deacetylase inhibitors: insights into mechanisms of lethality.

Rosato RR, Grant S.

Expert Opin Ther Targets. 2005 Aug;9(4):809-24. Review.


Modulation of sensitivity to doxorubicin by the histone deacetylase inhibitor sodium butyrate in breast cancer cells.

Louis M, Rosato RR, Battaglia E, Néguesque A, Lapotre A, Grant S, Bagrel D.

Int J Oncol. 2005 Jun;26(6):1569-74.


Costimulation with interleukin-4 and interleukin-10 induces mast cell apoptosis and cell-cycle arrest: the role of p53 and the mitochondrion.

Bouton LA, Ramirez CD, Bailey DP, Yeatman CF, Yue J, Wright HV, Domen J, Rosato RR, Grant S, Fischer-Stenger K, Ryan JJ.

Exp Hematol. 2004 Dec;32(12):1137-45.


The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress.

Louis M, Rosato RR, Brault L, Osbild S, Battaglia E, Yang XH, Grant S, Bagrel D.

Int J Oncol. 2004 Dec;25(6):1701-11.


Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.

Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant S.

Leukemia. 2004 Nov;18(11):1780-8.


The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S, Grant S.

Cancer Res. 2004 Apr 1;64(7):2590-600.


Histone deacetylase inhibitors in clinical development.

Rosato RR, Grant S.

Expert Opin Investig Drugs. 2004 Jan;13(1):21-38. Review.


Histone deacetylase inhibitors in cancer therapy.

Rosato RR, Grant S.

Cancer Biol Ther. 2003 Jan-Feb;2(1):30-7. Review.


Inverse correlation between insulin-like growth factor (IGF)-binding protein-5 and IGF-I and II during postnatal development of the anterior pituitary gland.

González-Parra S, Rosato RR, Chowen JA, Argente J, Groffen C, Dits N, Drop SL.

Horm Res. 2002;57(1-2):10-4.


mRNA expression patterns of the IGF system during mouse limb bud development, determined by whole mount in situ hybridization.

van Kleffens M, Groffen C, Rosato RR, van den Eijnde SM, van Neck JW, Lindenbergh-Kortleve DJ, Zwarthoff EC, Drop SL.

Mol Cell Endocrinol. 1998 Mar 16;138(1-2):151-61.


Gene expression of the insulin-like growth factor system during mouse kidney development.

Lindenbergh-Kortleve DJ, Rosato RR, van Neck JW, Nauta J, van Kleffens M, Groffen C, Zwarthoff EC, Drop SL.

Mol Cell Endocrinol. 1997 Sep 19;132(1-2):81-91.


IGF, type I IGF receptor and IGF-binding protein mRNA expression in kidney and liver of potassium-depleted and normal rats infused with IGF-I.

van Neck JW, Flyvbjerg A, Schuller AG, Rosato RR, Groffen C, van Kleffens M, Lindenbergh-Kortleve D, Dørup I, Drop SL.

J Mol Endocrinol. 1997 Aug;19(1):59-66.


Effect of chronic thyroid hormone treatment on cycling, ovulation, serum reproductive hormones and ovarian LH and prolactin receptors in rats.

Jahn GA, Moya G, Jammes H, Rosato RR.

Endocrine. 1995 Feb;3(2):121-7. doi: 10.1007/BF02990063.


Effects of chronic thyroid hormone administration on pregnancy, lactogenesis and lactation in the rat.

Rosato RR, Gimenez MS, Jahn GA.

Acta Endocrinol (Copenh). 1992 Dec;127(6):547-54.


Venezuelan equine encephalomyelitis: report of an outbreak associated with jungle exposure.

Sanchez JL, Takafuji ET, Lednar WM, LeDuc JW, Macasaet FF, Mangiafico JA, Rosato RR, Driggers DP, Haecker JC.

Mil Med. 1984 Nov;149(11):618-21. No abstract available.


Retention of fluorescent antigenicity of virus-infected cells on spotslides under various conditions of storage.

Rosato RR, Brand OM, Bagley LR.

J Virol Methods. 1982 Dec;5(5-6):279-84.


Structural polypeptides of Hazara virus.

Foulke RS, Rosato RR, French GR.

J Gen Virol. 1981 Mar;53(Pt 1):169-72.


Supplemental Content

Loading ...
Support Center